retatrutide side effects clinical trials Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Retatrutide UK 2026: Phase 3

The SURPASS-1 through SURPASS-5 trials demonstrated that 91% of patients on tirzepatide achieved an A1C below 7% (the standard treatment target), compared to approximately 68% on liraglutide in comparable studies

Perspectives in GLP-1 research: new targets, new receptors

[DOI] [PubMed] [Google Scholar] 9.Siu FY, et al

Continuous use: ~18% reduction in heart attack, stroke, and death Stop the drug: 6 months +4% risk 1 year +14% 1.5 years benefit erased 2 years +22% risk It takes 3 years to build protection and ~11.5 years to lose it

Albiglutide in clinical trials The clinical trials of albiglutide comparing with that of insulin glargine in patients with T2D were conducted in a study series entitled HARMONY

Liu L., Chen J., Wang L., Chen C., and Chen L., Association Between Different GLP1 Receptor Agonists and Gastrointestinal Adverse Reactions: A RealWorld Disproportionality Study Based on FDA Adverse Event Reporting System Database, Frontiers in Endocrinology 13 (2022): 1043789